ASK REDCHAT ANYTHING ABOUT NEUROGENE INC.
Neurogene Inc. (NASDAQ: NGNE)
Listen to this Section
$27.49
+0.0100
(
+0.04% )
0.0K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| NGN-401DetailsRare genetic disease, Rett syndrome |
Phase 1/2 |
| NGN-101DetailsRare genetic disease, Batten Disease |
Phase 1/2 |
Market Data
|
| Open |
$27.49 |
| Previous Close |
$27.48 |
| Volume |
0.0K |
| Market Cap |
$414.33M |
| Day Range |
$27.41 - $27.47 |
| 52 Week Range |
$14.65 - $37.27 |
| Shares Outstanding |
15.80M |
| Change % |
+0.04% |
| Net Change |
▲ 0.0100 |
| Insider Ownership |
0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2023 |
| Country | Canada |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-240,683.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-08-14 |
Sale |
-5000.00 |
Smith Sean Michael |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
2 |
Nov 14, 2025 |
| 8-k |
8K-related |
52 |
Nov 13, 2025 |
| 10-q |
Quarterly Reports |
78 |
Nov 13, 2025 |
| 8-k |
8K-related |
37 |
Nov 12, 2025 |
| 8-k |
8K-related |
51 |
Nov 06, 2025 |
| 8-k |
8K-related |
50 |
Oct 09, 2025 |
| 10-q |
Quarterly Reports |
78 |
Aug 11, 2025 |
| 8-k |
8K-related |
52 |
Aug 11, 2025 |
| 8-k |
8K-related |
50 |
Jun 30, 2025 |
| 4 |
Insider transactions |
3 |
Jun 13, 2025 |